E. Cassidy

577O PRINCE: Interim analysis of the phase Ib study of 177Lu-PSMA-617 in combination with pembrolizumab for metastatic castration resistant prostate cancer (mCRPC)

L. Horvath, T. Akhurst, I. Davis, 2021, Annals of Oncology.